Skip to main content

Advertisement

Table 1 Liver involvement as a poor prognostic factor in different therapeutic studies

From: Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

Author Treatment N Liver involvement Median survival (months) 5-year survival p values
Chamberlain (2000) [46] Surgical resection 85 0–25% 90%  
25–50% 83%
50–75% 47 80%
> 75% 24
Yao (2001) [47] Surgical resection 16 ≤4 liver metastases 46 <  0.05
> 4 liver metastases 20
Gupta (2005) [48] TAE or TACE 123 0–25% 86  
25–50% 30 <  0.10
50–75% 39 <  0.17
> 75% 20 <  0.05
Kwekkeboom (2008) [14] PRRT 310 None > 48  
Moderate > 48  
Extensive 25 <  0.01
  1. Legend: TAE transarterial (bland) embolization, TACE transarterial chemoembolization, PRRT peptide receptor radionuclide therapy